Financial Data and Key Metrics Changes - For Q4 2025, the company reported worldwide revenue of $1.26 billion, a 13% increase from $1.11 billion in Q4 2024, with organic growth at 12% [15][16] - U.S. revenue reached $892 million in Q4 2025, up 11% from $803 million in Q4 2024 [15] - International revenue grew 18% to $368 million in Q4 2025, with organic growth at 15% [16] - Gross profit for Q4 was $799.8 million, representing 63.5% of revenue, an increase from 59.4% in Q4 2024 [17] - Operating income was $331.5 million, or 26.3% of revenue, compared to $209.5 million, or 18.8% of revenue, in Q4 2024 [18] - Net income for Q4 was $265.1 million, equating to $0.68 per share [18] - The company closed the quarter with approximately $2 billion in cash and cash equivalents, indicating strong financial flexibility [18] Business Line Data and Key Metrics Changes - The rollout of the Dexcom G7 15-day system has received positive feedback, enhancing customer experience and potentially increasing market share [6][12] - The company is focusing on improving customer experience through new digital support systems and AI integration [7][8] - The early access launch of Dexcom Smart Basal aims to improve outcomes for Type 2 diabetes management [8] Market Data and Key Metrics Changes - The international business showed strength, particularly in Germany, the United Kingdom, and France, with France being one of the fastest-growing markets due to Type 2 access expansion [16] - The company anticipates that international market opportunities could surpass those in the U.S. over time [11] Company Strategy and Development Direction - The company aims to be the premier glucose sensing solution, focusing on sensor accuracy, reliability, and connectivity [6] - Strategic priorities include enhancing customer experience, expanding international market share, and driving growth through product innovation [10][11] - The company plans to introduce new products in 2026, including Stelo and a new CGM system for international markets [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in metabolic health management and the impact of upcoming Medicare coverage for Type 2 non-insulin users [24][26] - The company expects total revenue for 2026 to be in the range of $5.16 billion to $5.25 billion, reflecting growth of 11%-13% [19][20] - Management highlighted the importance of maintaining gross margin improvements and operational efficiencies while investing in new facilities [20][47] Other Important Information - The company has surpassed $1 billion in free cash flow for the first time in 2025 [19] - An Investor Day is planned for May 2026 to provide further details on the company's outlook [13] Q&A Session Summary Question: Discussion on the company's glucose sensing journey and market potential - Management believes the company is in the early stages of addressing metabolic health issues, with significant growth opportunities in Type 2 coverage expected in the next 12-24 months [24][26] Question: Inquiry about CMS coverage for Type 2 non-insulin users - Management is optimistic about upcoming CMS coverage decisions and is preparing for potential impacts on market access [30][33] Question: Impact of the 15-day product rollout on margins and new markets - The 15-day product is expected to contribute to margins over time, with significant opportunities for international expansion [36][39] Question: Discussion on operating expenses and investments - Increased operating expenses are primarily due to investments in the new Ireland manufacturing facility, which will enhance future production capabilities [46][47] Question: Utilization rates among different user segments - Utilization rates remain stable across various user segments, with high engagement expected to drive further growth [51][52] Question: Revenue outlook and new patient dynamics for 2026 - Revenue growth will depend on patient retention, utilization, and pricing strategies, with a focus on maintaining a stable user base [56][60] Question: Stability of the U.S. sensor uptake trends - Management noted improvements in sensor deployment and stable user retention, contributing to positive sell-through trends [64][66] Question: Pricing dynamics related to Medicare coverage - Pricing strategies will be influenced by competitive bidding processes, with expectations for stable pricing amidst increased volume [72][74] Question: International market growth strategies - The company plans to deepen its presence in existing markets and expand into new regions, with a focus on generating evidence to support market access [80][82]

Financial Data and Key Metrics Changes - The company reported worldwide revenue of $1.21 billion for Q3 2025, a 22% increase compared to $994 million in Q3 2024, with organic revenue growth of 20% [20][21] - U.S. revenue reached $852 million, up 21% from $702 million in the same quarter last year [20][21] - Gross profit was $741.3 million, representing 61.3% of revenue, down from 63.0% in Q3 2024 [22] - Operating income was $272.9 million, or 22.6% of revenue, compared to $212.0 million, or 21.3% in Q3 2024 [24] - Net income for Q3 was $242.5 million, or $0.61 per share, marking the highest quarterly earnings per share in the company's history [24] Business Line Data and Key Metrics Changes - The company experienced strong growth in Type 2 diabetes segments, with new customer starts increasingly coming from this population due to expanded coverage [8][20] - The introduction of Dexcom Smart Basal aims to enhance the management of basal insulin for Type 2 customers, addressing their specific needs [11][12] - Stelo surpassed $100 million in revenue within its first year, indicating strong market acceptance and growth potential [13][14] Market Data and Key Metrics Changes - International revenue grew 22% to $357.4 million, with organic growth of 18%, marking the third consecutive quarter of accelerating international growth [21] - France and Canada were highlighted as strong markets, with France showing consistent growth due to new coverage [21] Company Strategy and Development Direction - The company is focused on expanding coverage for Type 2 diabetes patients, aiming to secure access for the entire population of over 25 million Americans [9][10] - The launch of the G7 15 Day system is anticipated to enhance the company's product offerings and market position [14][15] - The company is committed to improving customer experience through new digital platforms and ongoing software updates [16][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, emphasizing the importance of expanding access to CGM for Type 2 diabetes patients [8][9] - The company acknowledged challenges related to sensor deployment but indicated improvements have been made, leading to a positive outlook for Q4 and beyond [34][35] - Management expects to return to record levels of new patient starts in 2026, driven by existing coverage and potential new coverage opportunities [77] Other Important Information - The company raised its revenue guidance for 2025 to a range of $4.630 billion to $4.650 billion, reflecting approximately 15% growth for the year [25] - Operating expenses increased to $468.4 million in Q3 2025, up from $413.9 million in Q3 2024, as the company continues to invest in R&D [24] Q&A Session Summary Question: Insights on 2026 growth estimates - Management refrained from providing specific guidance for 2026 but indicated a positive outlook based on current coverage and access to CGM [30][31] Question: G7 performance and deployment issues - Management confirmed that deployment challenges have been addressed, and they expect improvements in new starts and prescribing patterns moving forward [34][35] Question: Growth in new patient segments - The company noted strong performance across all Type 2 markets, including intensive and non-insulin users, and is actively exploring marketing strategies to drive uptake [40][41] Question: Expanded coverage potential for 2026 - Management stated that the base case for guidance includes current coverage, with potential for expanded coverage being a positive but not guaranteed factor [44][45] Question: 15 Day sensor launch and revenue contribution - The company is excited about the upcoming broader launch of the 15 Day sensor, with expectations for it to contribute to revenue growth in 2026 [52][53] Question: Gross margin and scrap rate issues - Management indicated that scrap and freight issues have impacted margins but expect improvements as they transition back to more cost-efficient shipping methods [70][72]

Financial Data and Key Metrics Changes - The company is guiding for 14% to 15% top-line growth for the year, with an expectation of about 200 basis points of operating margin leverage [14][30] - The company aims to execute on its 2025 commitments after not meeting them last year, emphasizing the importance of achieving revenue and operating margin targets [10][30] Business Line Data and Key Metrics Changes - The company reported a strong performance in the continuous glucose monitoring (CGM) segment, with a focus on expanding coverage and access globally [11][15] - The Stelo product has generated $100 million in revenue within its first twelve months, indicating strong market acceptance [41] Market Data and Key Metrics Changes - The company is seeing increased coverage for CGM, with more people having access than currently using the technology, suggesting significant growth potential [7][15] - International markets are expected to contribute to growth, with a tiered pricing model allowing for incremental revenue from new markets [36] Company Strategy and Development Direction - The company is focused on building a metabolic health platform, with continued emphasis on diabetes management while exploring broader applications [8] - Strategic priorities include expanding international presence, enhancing commercial infrastructure, and preparing for increased coverage in type two diabetes [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong double-digit growth in the foreseeable future, driven by expanding healthcare coverage and market opportunities [15] - The management team is actively working on a long-range plan (LRP) to provide clearer guidance to investors, expected to be released soon [16][18] Other Important Information - The company addressed concerns regarding the reliability and accuracy of its G7 product, stating improvements have been made and deployment challenges have been resolved [21][22] - The upcoming launch of a 15-day sensor is expected to enhance product offerings and customer experience [26][29] Q&A Session Summary Question: What are the strategic priorities for the next 12 to 24 months? - The company emphasized executing on 2025 commitments, expanding CGM coverage, and scaling operations [10][11] Question: How does the company view growth moving forward? - Management sees strong double-digit growth potential based on existing and upcoming healthcare coverage [15] Question: What is the outlook for international markets? - The company plans to push harder into international markets with a tiered pricing model and expects significant growth opportunities [36] Question: How is the company addressing recent concerns about G7 reliability? - Management stated that improvements have been made and that they are confident in the product's performance [21][22] Question: What is the expected impact of the 15-day sensor launch? - The company is confident in the quality of the 15-day sensor and is preparing for a smooth transition for users [26][29] Question: What is the timeline for the randomized controlled trial (RCT) for type two diabetes? - The RCT is expected to read out in the first part of next year, with results anticipated to support access submissions globally [52][53] Question: How does the company view competitive threats from Abbott's upcoming products? - Management believes that their existing products, particularly the G7, provide critical safety features that will maintain competitive advantage [71][72]

Financial Data and Key Metrics Changes - The company reported worldwide revenue of $1,036 million for Q1 2025, a 12% increase compared to $921 million in Q1 2024, with organic revenue growth of 14% [18] - U.S. revenue totaled $751 million, up 15% from $653 million in Q1 2024, driven by strong new customer demand [19] - International revenue grew 7% to $286 million, with organic growth of 12% [21] - Gross profit was $596.2 million, representing 57.5% of revenue, down from 61.8% in Q1 2024 [23] - Operating income was $143.1 million, or 13.8% of revenue, compared to $140.2 million in the same quarter of 2024 [24] - Adjusted EBITDA was $230.4 million, or 22.2% of revenue, compared to $220.9 million, or 24% of revenue in Q1 2024 [25] - Net income for Q1 was $127.7 million, or $0.32 per share [26] Business Line Data and Key Metrics Changes - The company experienced record levels of new customer demand, particularly from the Type 2 non-insulin using population [9][10] - The introduction of Stello, the first over-the-counter CGM, and broader access in the Type 2 market contributed to increased customer starts [10][12] - The company launched a 180-day data look-back feature for the Stello app, enhancing customer experience [13] Market Data and Key Metrics Changes - The company secured access at two of the three largest PBMs for diabetes patients, which is expected to cover nearly six million people with Type 2 diabetes by the end of the year [10][11] - International business showed strength in Japan and France, with continued growth in the Type 2 landscape [22] Company Strategy and Development Direction - The company is focused on expanding coverage for Type 2 diabetes patients and enhancing customer experience through technology and software updates [10][12] - The introduction of the 15-day G7 system is expected to set a new industry standard for sensor accuracy and wear time [16] - The company is committed to addressing FDA concerns following a warning letter and is working on corrective actions [15][102] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating supply dynamics and maintaining customer care during the transition period [6][19] - The company reaffirmed its revenue guidance of $4.6 billion for the year, representing 14% growth, while adjusting gross margin guidance to approximately 62% [27][29] - Management is optimistic about the potential for broader Type 2 coverage and the positive reception of CGM technology in the healthcare landscape [10][110] Other Important Information - The company announced a $750 million share repurchase program, reflecting strong cash flow and financial position [26] - Management highlighted the importance of evidence-based data in driving changes to standards of care and expanding access globally [11] Q&A Session Summary Question: Did supply have any impact on the revenue growth? - Management indicated that supply dynamics were normalized by the end of the quarter, and strong new patient performance was observed despite previous challenges [35] Question: Why is full-year guidance unchanged despite strong Q1 growth? - Management stated that it is prudent to wait and see how the year unfolds before adjusting guidance, emphasizing the importance of a full-year perspective [42] Question: What are the trends in Type 2 patient utilization and reorder rates? - Management reported good retention and utilization rates among Type 2 patients, particularly those with reimbursement coverage [50] Question: How exposed is the company to a potential recession? - Management believes the company is well-positioned to weather economic downturns due to the cost-saving benefits of its products [58][60] Question: What is the status of the FDA warning letter? - Management confirmed that the warning letter does not restrict new submissions or approvals and that they are making progress in addressing FDA concerns [102] Question: What is the timeline for the RCT data readout for Type 2 non-insulin users? - Management anticipates finishing enrollment in the first half of the year, with initial data readout expected late this year or early next year [112]